Blocking oestradiol synthesis pathways with potent and selective coumarin derivatives

References

• DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014;64:52–62.
   PubMed Web of Science ®Google Scholar
• Pasqualini J, Chetrite G, Blacker M, et al. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J Clin Endocrinol Metab 1996;81:1460–4.
   PubMed Web of Science ®Google Scholar
• Vihko P, Härkönen P, Soronen P, et al. 17β-Hydroxysteroid dehydrogenases – their role in pathophysiology. Mol Cell Endocrinol 2004;215:83–8.
   PubMed Web of Science ®Google Scholar
• Hanamura T, Niwa T, Gohno T, et al. Possible role of the aromatase-independent steroid metabolism pathways in hormone responsive primary breast cancers. Breast Cancer Res Treat 2014;143:69–80.
   PubMed Web of Science ®Google Scholar
• Frycz BA, Murawa D, Wysocki-Borejsza M, et al. Expression of 17β-hydroxysteroid dehydrogenase type 1 in gastric cancer. Biomed Pharmacother 2013;67:651–7.
   PubMed Web of Science ®Google Scholar
• Tomaszewska A, Roszak A, Pawlik P, et al. Increased 17ß-hydroxysteroid dehydrogenase type 1 levels in primary cervical cancer. Biomed Pharmacother Biome´decine Pharmacothe´rapie 2015;72:179–83.
   PubMed Web of Science ®Google Scholar
• Dassen H, Punyadeera C, Kamps R, et al. Estrogen metabolizing enzymes in endometrium and endometriosis. Hum Reprod 2007;22:3148–58.
   PubMed Web of Science ®Google Scholar
• Maltais R, Ayan D, Trottier A. Discovery of a non-estrogenic irreversible inhibitor of 17β-hydroxysteroid dehydrogenase type 1 from 3-substituted-16β-(m-carbamoylbenzyl)-estradiol derivatives. J Med Chem 2013;57:204–22.
   PubMed Web of Science ®Google Scholar
• Maltais R, Trottier A, Delhomme A, et al. Identification of fused 16β,17β-oxazinone-estradiol derivatives as a new family of non-estrogenic 17β-hydroxysteroid dehydrogenase type 1 inhibitors. Eur J Med Chem 2015;93:470–80.
   PubMed Web of Science ®Google Scholar
• Messinger J, Husen B, Koskimies P, et al. Estrone C15 derivatives-a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors. Mol Cell Endocrinol 2009;301:216–24.
   PubMed Web of Science ®Google Scholar
• Abdelsamie AS, van Koppen CJ, Bey E, et al. Treatment of estrogen-dependent diseases: design, synthesis and profiling of a selective 17ß-HSD1 inhibitor with sub-nanomolar IC50 for a proof-of-principle study. Eur J Med Chem 2017;127:944–57.
   PubMed Web of Science ®Google Scholar
• Lilienkampf A, Karkola S, Alho-Richmond S, et al. Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core. J Med Chem 2009;52:6660–71.
   PubMed Web of Science ®Google Scholar
• Messinger J, Hirvelä L, Husen B, et al. Novel non-steroidal inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1. Mol Cell Endocrinol 2006;104:137–50.
   Google Scholar
• Niinivehmas SP, Manivannan E, Rauhamäki S, et al. Identification of estrogen receptor ligands with virtual screening techniques. J Mol Graph Model 2016;64:30–9.
   PubMed Web of Science ®Google Scholar
• Olmedo D, Sancho R, Bedoya LM, et al. 3-phenylcoumarins as inhibitors of HIV-1 replication. Molecules 2012;17:9245–57.
   PubMed Web of Science ®Google Scholar
• Kabeya LM, da Silva CHTP, Kanashiro A, et al. Inhibition of immune complex-mediated neutrophil oxidative metabolism: a pharmacophore model for 3-phenylcoumarin derivatives using GRIND-based 3D-QSAR and 2D-QSAR procedures. Eur J Med Chem 2008;43:996–1007.
   PubMed Web of Science ®Google Scholar
• Leitão A, Andricopulo AD, Oliva G, et al. Structure-activity relationships of novel inhibitors of glyceraldehyde-3-phosphate dehydrogenase. Bioorg Med Chem Lett 2004;14:2199–204.
   PubMed Web of Science ®Google Scholar
• Delogu GL, Serra S, Quezada E, et al. Monoamine oxidase (MAO) inhibitory activity: 3-phenylcoumarins versus 4-hydroxy-3-phenylcoumarins. Chem Med Chem 2014;9:1672–6.
   Google Scholar
• Buu-Hoi NP, Saint-Ruf G, Lobert B. Oxygen heterocycles. Part XIV. Hydroxylated 3-aryl- and 3-pyridyl-coumarins. J Chem Soc C Org 1969;16:2069–70.
   Web of Science ®Google Scholar
• Kirkiacharian S, Chidiack H, Philibert D, et al. Binding affinity to steroid hormone receptors and antiproliferative action on MCF—7 cells of coumarinic derivatives and isoflavonoids. Ann Pharm Fr 1999;57:332–9.
   PubMedGoogle Scholar
• Quezada E, Delogu G, Picciau C, et al. Synthesis and vasorelaxant and platelet antiaggregatory activities of a new series of 6-halo-3-phenylcoumarins. Molecules 2010;15:270–9.
   PubMed Web of Science ®Google Scholar
• Pasanen M. Human placental aromatase activity: use of a C18 reversed-phase cartridge for separation of tritiated water or steroid metabolites in placentas from both smoking and non-smoking mothers in vitro. Biol Res Pregnancy Perinatol 1985;6:94–9.
   PubMedGoogle Scholar
• Holt A, Sharman DF, Baker GB, Palcic MM. A continuous spectrophotometric assay for monoamine oxidase and related enzymes in tissue homogenates. Anal Biochem 1997;244:384–92.
   PubMed Web of Science ®Google Scholar
• Korhonen LE, Rahnasto M, Mähönen NJ, et al. Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem 2005;48:3808–15.
   PubMed Web of Science ®Google Scholar
• Mazumdar M, Fournier D, Zhu DW, et al. Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy. Biochem J 2009;424:357–66.
   PubMed Web of Science ®Google Scholar
• Ghosh D, Griswold J, Erman M, Pangborn W. Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature 2009;457:219–23.
   PubMed Web of Science ®Google Scholar
• Binda C, Wang J, Pisani L, et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem 2007;50:5848–52.
   PubMed Web of Science ®Google Scholar
• Sansen S, Yano JK, Reynald RL, et al. Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J Biol Chem 2007;282:14348–55.
   PubMed Web of Science ®Google Scholar
• Niinivehmas SP, Salokas K, Lätti S, et al. Ultrafast protein structure-based virtual screening with Panther. J Comput Aided Mol Des 2015;29:989–1006.
   PubMed Web of Science ®Google Scholar
• Vainio MJ, Puranen JS, Johnson MS. ShaEP: molecular overlay based on shape and electrostatic potential. J Chem Inf Model 2009;49:492–502.
   PubMed Web of Science ®Google Scholar
• Lehtonen JV, Still DJ, Rantanen VV, et al. BODIL: a molecular modeling environment for structure-function analysis and drug design. J Comput Aided Mol Des 2004;18:401–19.
   PubMed Web of Science ®Google Scholar
• Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996;14:33–8.
   PubMed Web of Science ®Google Scholar
• Koivunen JT, Nissinen L, Käpylä J, et al. Fluorescent small molecule probe to modulate and explore a2b1 integrin function. J Am Chem Soc 2011;133:14558–61.
   PubMed Web of Science ®Google Scholar
• Virtanen SI, Niinivehmas SP, Pentikäinen OT. Case-specific performance of MM-PBSA, MM-GBSA, and SIE in virtual screening. J Mol Graph Model 2015;62:303–18.
   PubMed Web of Science ®Google Scholar
• Frydenvang K, Lash LL, Naur P, et al. Full domain closure of the ligand-binding core of the ionotropic glutamate receptor iGluR5 induced by the high affinity agonist dysiherbaine and the functional antagonist 8,9-dideoxyneodysiherbaine. J Biol Chem 2009;284:14219–29.
   PubMed Web of Science ®Google Scholar
• Postila PA, Kaszuba K, Kuleta P, et al. Atomistic determinants of co-enzyme Q reduction at the Qi-site of the cytochrome bc1 complex. Sci Rep 2016;6:33607.
   PubMed Web of Science ®Google Scholar
• Kuleta P, Sarewicz M, Postila P, et al. Identifying involvement of Lys251/Asp252 pair in electron transfer and associated proton transfer at the quinone reduction site of Rhodobacter capsulatus cytochrome bc1. Biochim Biophys Acta Bioenerg 2016;1857:1661–8.
   PubMed Web of Science ®Google Scholar
• Lash LL, Sanders JM, Akiyama N, et al. Novel analogs and stereoisomers of the marine toxin neodysiherbaine with specificity for kainate receptors. J Pharmacol Exp Ther 2008;324:484–96.
   PubMed Web of Science ®Google Scholar
• Postila PA, Swanson GT, Pentikäinen OT. Exploring kainate receptor pharmacology using molecular dynamics simulations. Neuropharmacology 2010;58:515–27.
   PubMed Web of Science ®Google Scholar
• Leanne Lash-Van Wyhe L, Postila PA, Tsubone K, et al. Pharmacological activity of C10-substituted analogs of the high-affinity kainate receptor agonist dysiherbaine. Neuropharmacology 2010;58:640–9.
   PubMed Web of Science ®Google Scholar
• Sawicki MW, Erman M, Puranen T, et al. Structure of the ternary complex of human 17beta-hydroxysteroid dehydrogenase type 1 with 3-hydroxyestra-1,3,5,7-tetraen-17-one (equilin) and NADP+. Proc Natl Acad Sci USA 1999;96:840–5.
   PubMed Web of Science ®Google Scholar
• Virtanen SI, Pentikäinen OT. Efficient virtual screening using multiple protein conformations described as negative images of the ligand-binding site. J Chem Inf Model 2010;50:1005–11.
   PubMed Web of Science ®Google Scholar
• Niinivehmas SP, Virtanen SI, Lehtonen JV, et al. Comparison of virtual high-throughput screening methods for the identification of phosphodiesterase-5 inhibitors. J Chem Inf Model 2011;51:1353–63.
   PubMed Web of Science ®Google Scholar
• Matos MJ, Santana L, Uriarte E3. Phenyl-coumarin. Acta Crystallogr Sect E Struct Reports Online 2012;68:0–6.
   Google Scholar
• Aka JA, Mazumdar M, Chen CQ, et al. 17beta-hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol production. Mol Endocrinol 2010;24:832–45.
   PubMedGoogle Scholar
• Abraham K, Wöhrlin F, Lindtner O, et al. Toxicology and risk assessment of coumarin: focus on human data. Mol Nutr Food Res 2010;54:228–39.
   PubMed Web of Science ®Google Scholar
• Raunio H, Rahnasto-Rilla M. CYP2A6: genetics, structure, regulation, and function. Drug Metabol Drug Interact 2012;27:73–88.
   PubMedGoogle Scholar
• Matos MJ, Vazquez-Rodriguez S, Uriarte E, et al. MAO inhibitory activity modulation: 3-phenylcoumarins versus 3-benzoylcoumarins. Bioorganic Med Chem Lett 2011;21:4224–7.
   PubMed Web of Science ®Google Scholar
• Rauhamäki S, Postila PA, Niinivehmas S, et al. Structure-activity relationship analysis of 3-phenylcoumarin-based monoamine oxidase B inhibitors. Front Chem 2018;6:41.
   PubMed Web of Science ®Google Scholar
• Patil PO, Bari SB, Firke SD, et al. A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer’s disease. Bioorganic Med Chem 2013;21:2434–50.
   PubMed Web of Science ®Google Scholar
• Matos MJ, Terán C, Pérez-Castillo Y, et al. Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors. J Med Chem 2011;54:7127–37.
   PubMed Web of Science ®Google Scholar
• Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett 2005;227:115–24.
   PubMed Web of Science ®Google Scholar
• Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol 2003;86:225–30.
   PubMed Web of Science ®Google Scholar
• Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 2010;53:2719–40.
   PubMed Web of Science ®Google Scholar